MM Treatment: CAR T-Cell Therapy Selection and Insurance Considerations
The panel discusses the utilization of CAR T-cell therapy for patients with multiple myeloma, highlighting treatment selection, sequencing, and insurance considerations.
Video content above is prompted by the following questions:
- How might you consider sequencing therapies for this patient? Please describe how you would approach treating this patient in your practice.
- What factors impact your decision?
- How do you incorporate patient preferences and quality of life considerations into the discussion when determining the sequencing of bispecifics and CAR T-cell therapy in R/R MM?
- Can BCMA-targeting bispecifics be used in patients who have received prior BCMA targeting CAR-T therapies?
- Might you consider a different target?
- Might your strategy differ if the patient had received ide-cel instead of cilta-cel?
Newsletter
Stay up to date on recent advances in the multidisciplinary approach to cancer.
Recent Videos
Related Content
